within Pharmacolibrary.Drugs.ATC.D;

model D07AB08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AB08</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Desonide is a low-potency topical corticosteroid used primarily to treat a variety of skin conditions such as atopic dermatitis, eczema, and psoriasis. It exerts anti-inflammatory and antipruritic effects. Desonide is widely approved and used today, especially suitable for sensitive skin or use in pediatric populations due to its low potency.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for desonide applied topically in adults with healthy skin, as no direct clinical PK studies or compartmental models are published.</p><h4>References</h4><ol><li><p>Sun, Y, et al., &amp; Yang, G (2024). Evaluation of Bioequivalence and Pharmacokinetic Profiles for Topical Desonide Cream Using Chinese Skins. <i>Skin pharmacology and physiology</i> 37(4-6) 70–79. DOI:<a href=&quot;https://doi.org/10.1159/000540782&quot;>10.1159/000540782</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39159613/&quot;>https://pubmed.ncbi.nlm.nih.gov/39159613</a></p></li><li><p>Ma, Q, et al., &amp; Li, X (2021). Nanoemulgel for Improved Topical Delivery of Desonide: Formulation Design and Characterization. <i>AAPS PharmSciTech</i> 22(5) 163–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-021-02035-5&quot;>10.1208/s12249-021-02035-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34031790/&quot;>https://pubmed.ncbi.nlm.nih.gov/34031790</a></p></li><li><p>Kahanek, N, et al., &amp; Hebert, A (2008). Desonide: a review of formulations, efficacy and safety. <i>Expert opinion on investigational drugs</i> 17(7) 1097–1104. DOI:<a href=&quot;https://doi.org/10.1517/13543784.17.7.1097&quot;>10.1517/13543784.17.7.1097</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18549345/&quot;>https://pubmed.ncbi.nlm.nih.gov/18549345</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AB08;
